التفاصيل البيبلوغرافية
| العنوان: |
The Safety and Efficacy of KAI-1678- An Inhibitor of Epsilon Protein Kinase C (ε PKC)-Versus Lidocaine and Placebo for the Treatment of Postherpetic Neuralgia: A Crossover Study Design. |
| المؤلفون: |
Cousins, Michael J., Pickthorn, Karen, Huang, Saling, Critchley, Linda, Bell, Gregory |
| المصدر: |
Pain Medicine; Apr2013, Vol. 14 Issue 4, p533-540, 8p, 2 Charts, 3 Graphs |
| مصطلحات موضوعية: |
HERPES zoster treatment, LIDOCAINE, NEURALGIA, CONFIDENCE intervals, CROSSOVER trials, PROTEIN kinases, QUESTIONNAIRES, RESEARCH funding, STATISTICAL sampling, SCALE analysis (Psychology), T-test (Statistics), PILOT projects, DATA analysis software, DESCRIPTIVE statistics, THERAPEUTICS |
| مصطلحات جغرافية: |
AUSTRALIA |
| مستخلص: |
Objective. Postherpetic neuralgia ( PHN) occurs in approximately 10-20% of patients with herpes zoster, and the risk increases with age. In this clinical trial, we evaluated the analgesic properties of KAI-1678-an inhibitor of epsilon protein kinase C-in the treatment of neuropathic pain in patients with PHN. Design. The study was a three-treatment period, double-blind, randomized, placebo and active comparator crossover trial evaluating subcutaneous infusions of KAI-1678 (25 mg), placebo, and lidocaine hydrochloride (700 mg; active comparator). Patients. A total of 17 men and 6 women ( N = 23) were enrolled after fulfilling diagnosis of PHN with pain persisting for ≥3 months after a segmental herpes zoster eruption. Patients had to have a mean average pain score of ≥4 points on an 11-point numerical rating scale ( NRS; ranging from 0 to 10) based on at least three daily entries prior to participation in the subsequent treatment period. Results. Overall, administration of KAI-1678 was generally safe and well tolerated. However, compared with placebo, KAI-1678 did not improve clinical pain scores as recorded using the NRS (0-10). In contrast, subcutaneous infusions of lidocaine were associated with a significant reduction in pain intensity at the end of the infusion. Conclusions. We conclude that KAI-1678 is not efficacious as an acute analgesic for chronic neuropathic pain because of PHN. However, for the first time, the results demonstrate that subcutaneous infusions of lidocaine are effective in treating neuropathic pain. The results of lidocaine treatment also indicate that the crossover study design was adequate to detect a clinically meaningful response in this analgesia study. [ABSTRACT FROM AUTHOR] |
|
Copyright of Pain Medicine is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
